



Discovery of first-in-Class WNK3 targeted selective inhibitor for cancer immunotherapy

Checkmate Therapeutics Inc.

Disease Area	Oncology
Product Type	Small molecule (kinase inhibitor)
Indication	Solid tumor
Target	WNK3 (WNK lysine deficient protein kinase 3)
Mechanism of Action	WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function
Competitiveness	<ol style="list-style-type: none"> 1. First-in-Class WNK3 selective inhibitor 2. Highly Potent and Selective to WNK3 -Compound CX003 demonstrates low nM potency (IC50=21nM) of WNK3 inhibition and excellent selectivity against WNK1 (42 folds). 3. Superior safety -It also shows superior cell viability in normal and immune cell line. 4. Concurrent impact on cancer and immune cells -It suppresses PD-L1 in tumor cells and activates T-Cells

Development Stage	Hit
Route of Administration	Oral administration





IP	
-----------	--

Discovery of first-in-Class WNK3 targeted selective inhibitor for cancer immunotherapy

Checkmate Therapeutics Inc.

Disease Area	Oncology
Product Type	Small molecule (kinase inhibitor)
Indication	Solid tumor
Target	WNK3 (WNK lysine deficient protein kinase 3)
Mechanism of Action	WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function
Competitiveness	<ol style="list-style-type: none"> 1. First-in-Class WNK3 selective inhibitor 2. Highly Potent and Selective to WNK3 -Compound CX003 demonstrates nM potency (IC₅₀=21nM) of WNK3 inhibition and excellent selectivity against WNK1 (42 folds). 3. Superior safety -It also demonstrates enhanced safety in normal cell lines. 4. Concurrent impact on cancer and immune cells -It suppresses PD-L1 in cancer cells and activates T-Cells

Development Stage	Hit
Route of Administration	Oral administration



IP	
-----------	--

Discovery of first-in-Class WNK3 targeted selective inhibitor for cancer immunotherapy

Checkmate Therapeutics Inc.

Disease Area	Oncology																																				
Product Type	Small molecule (kinase inhibitor)																																				
Indication	Solid tumor																																				
Target	WNK3 (WNK lysine deficient protein kinase 3)																																				
Mechanism of Action	WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function																																				
Competitiveness	<ol style="list-style-type: none"> 1. First-in-Class WNK3 selective inhibitor 2. Highly Potent and Selective to WNK3 -Compound CX003 demonstrates nM potency of WNK3 inhibition and excellent selectivity against WNK1. 3. Superior safety -It also demonstrates enhanced safety in normal cell lines. 4. Concurrent impact on cancer and immune cells -It suppresses PD-L1 in cancer cells and activates T-Cells 																																				
Development Stage	Hit																																				
Route of Administration	Oral administration																																				
Key Data	<div style="text-align: center;"> <p>In vitro potency & selectivity</p> </div> <div style="display: flex; justify-content: space-around; margin-top: 20px;"> <div style="border: 1px solid gray; padding: 5px; width: 45%;"> <p style="text-align: center;">PD-L1 axis</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th></th> <th colspan="6">SNU449 (liver cancer)</th> </tr> </thead> <tbody> <tr> <td>CX003 (µM)</td> <td>-</td><td>-</td><td>-</td><td>-</td><td>5</td><td>10</td> </tr> <tr> <td>pan-WNK inh (µM)</td> <td>-</td><td>5</td><td>10</td><td>-</td><td>-</td><td>-</td> </tr> </tbody> </table> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th></th> <th colspan="4">SNU201 (GBM)</th> </tr> </thead> <tbody> <tr> <td>CX003 (µM)</td> <td>-</td><td>0.2</td><td>1</td><td>-</td> </tr> <tr> <td>pan-WNK inh (µM)</td> <td>-</td><td>-</td><td>-</td><td>0.2</td> </tr> </tbody> </table> </div> <div style="border: 1px solid gray; padding: 5px; width: 45%;"> <p style="text-align: center;">Cytokine assay</p> </div> </div>		SNU449 (liver cancer)						CX003 (µM)	-	-	-	-	5	10	pan-WNK inh (µM)	-	5	10	-	-	-		SNU201 (GBM)				CX003 (µM)	-	0.2	1	-	pan-WNK inh (µM)	-	-	-	0.2
	SNU449 (liver cancer)																																				
CX003 (µM)	-	-	-	-	5	10																															
pan-WNK inh (µM)	-	5	10	-	-	-																															
	SNU201 (GBM)																																				
CX003 (µM)	-	0.2	1	-																																	
pan-WNK inh (µM)	-	-	-	0.2																																	
IP	Scheduled to applied for patent in 2026																																				